| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $100.0M | +25.1% |
| Cost of Revenue | $22.8M | +9.3% |
| Gross Profit | $77.2M | +30.7% |
| R&D Expense | $27.9M | +17.9% |
| SG&A Expense | $19.1M | -66.6% |
| Operating Income | -$16.3M | +24.6% |
| Income Tax | $0 | — |
| Net Income | -$21.5M | +20.9% |
| EPS (Basic) | -$0.66 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $21.7M | +61.5% |
| Short-term Investments | $39.4M | +0.1% |
| Accounts Receivable | $14.7M | +14.2% |
| Inventory | $16.9M | +26.3% |
| Current Assets | $94.1M | +15.7% |
| Total Assets | $105.6M | +11.5% |
| Current Liabilities | $17.8M | +17.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$11.0M | +38.7% |
| Capital Expenditures | $332K | +8.5% |
| Investing Cash Flow | -$332K | -103.7% |
| Financing Cash Flow | $19.6M | +353.0% |
| Free Cash Flow | -$11.3M | +37.9% |
| +29.0% |
| EPS (Diluted) | -$0.66 | +29.0% |
| Long-term Debt |
| $58.9M |
| -1.1% |
| Total Liabilities | $86.5M | -0.1% |
| Stockholders' Equity | $19.0M | +137.5% |